title: Temozolomide Treatment for Pediatric Refractory Anaplastic Ependymoma with Low MGMT Protein Expression.
abstract: The benefit of postoperative chemotherapy for anaplastic ependymoma remains unknown. We report two pediatric patients with refractory anaplastic ependymoma treated with temozolomide (TMZ). We did not detect O(6) -methylguanine-DNA methyltransferase (MGMT) promoter methylation in tumor samples; however, MGMT protein expression was low. With TMZ treatment, one patient had a 7-month complete remission; the other, stable disease for 15 months. Three other patients did not respond to TMZ; two had high and one low MGMT expression, and two showed no MGMT promoter methylation. These findings suggest that TMZ may be effective for pediatric refractory anaplastic ependymoma with low MGMT protein expression.
authors: Department of Hematology/Oncology, Nagano Children's Hospital, Azumino, Japan.|Department of Pediatrics, Shinshu University School of Medicine, Matsumoto, Japan.
authors: Kazutoshi
authors: K
authors: Komori
authors: Department of Hematology/Oncology, Nagano Children's Hospital, Azumino, Japan.|Department of Pediatrics, Shinshu University School of Medicine, Matsumoto, Japan.
authors: Ryu
authors: R
authors: Yanagisawa
authors: Department of Neurosurgery, Nagano Children's Hospital, Azumino, Japan.
authors: Yosuke
authors: Y
authors: Miyairi
authors: Department of Hematology/Oncology, Nagano Children's Hospital, Azumino, Japan.|Department of Pediatrics, Shinshu University School of Medicine, Matsumoto, Japan.
authors: Kazuo
authors: K
authors: Sakashita
authors: Department of Pediatrics, Matsumoto Dental University School of Dentistry, Shiojiri, Japan.
authors: Masaaki
authors: M
authors: Shiohara
authors: Department of Hematology/Oncology, Nagano Children's Hospital, Azumino, Japan.
authors: Ikuko
authors: I
authors: Fujihara
authors: Department of Pediatrics, Shinshu University School of Medicine, Matsumoto, Japan.
authors: Daisuke
authors: D
authors: Morita
authors: Department of Hematology/Oncology, Nagano Children's Hospital, Azumino, Japan.|Life Science Research Center, Nagano Children's Hospital, Azumino, Japan.
authors: Tomohiko
authors: T
authors: Nakamura
authors: Department of Clinical Pathology, Nagano Children's Hospital, Azumino, Japan.
authors: Yoshifumi
authors: Y
authors: Ogiso
authors: Department of Laboratory Medicine, Shinshu University Hospital, Matsumoto, Japan.
authors: Kenji
authors: K
authors: Sano
authors: Department of Neuro-Oncology/Neurosurgery, Saitama Medical University International Medical Center, Hidaka, Japan.
authors: Mitsuaki
authors: M
authors: Shirahata
authors: Division of Brain Tumor Translational Research, National Cancer Center Research Institute, Tokyo, Japan.
authors: Kohei
authors: K
authors: Fukuoka
authors: Division of Brain Tumor Translational Research, National Cancer Center Research Institute, Tokyo, Japan.
authors: Koichi
authors: K
authors: Ichimura
authors: Department of Neurosurgery, Nagano Children's Hospital, Azumino, Japan.
authors: Hiroaki
authors: H
authors: Shigeta
mesh_terms: D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000737:chemistry / Q000188:drug therapy*; D002675:Child, Preschool; D015254:DNA Modification Methylases / Q000032:analysis*; D045643:DNA Repair Enzymes / Q000032:analysis*; D003606:Dacarbazine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004806:Ependymoma / Q000737:chemistry / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D007223:Infant; D008297:Male; D000077204:Temozolomide; D025521:Tumor Suppressor Proteins / Q000032:analysis*
chemical_list: D018906:Antineoplastic Agents, Alkylating; D025521:Tumor Suppressor Proteins; D003606:Dacarbazine; D015254:DNA Modification Methylases; C515491:MGMT protein, human; D045643:DNA Repair Enzymes; D000077204:Temozolomide
keywords: MGMT; O6-methylguanine-DNA methyltransferase; ependymoma; temozolomide